Name: KU-0060648
Brand: Selleck Chemicals
SKU: S8045
Rating: 5 (11 reviews)

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	PI3K Akt mTOR GSK-3 ATM/ATR AMPK PDPK1 PTEN PP2A PDK
Other DNA-PK Inhibitors	Nedisertib (M3814) AZD7648 NU7441 (KU-57788) VX-984 NU7026 CC-115 YU238259 LTURM34 Compound 401

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human HeLa cells	Function assay			Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells, EC50=0.136 μM	23855836
MO59J-Fus1 cells	Function assay	1 μM		Inhibition of human DNA-PK autophosphorylation at S2056 in MO59J-Fus1 cells at 1 uM	23855836
HeLa	Function assay			Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells, EC50 = 0.136 μM.	23855836
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
HeLa	Function assay	1 uM	1 hr	Inhibition of DNA-PK in human HeLa cells assessed as phosphorylation of gammaH2AX at 1 uM treated 1 hr before 5 Gy ionizing radiation measured within 30 mins by immunofluorescence assay	23855836
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	582.71	Formula	C₃₃H₃₄N₄O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	881375-00-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CCN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7

Solubility

In vitro
Batch:

DMSO : 2 mg/mL (3.43 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	30%propylene glycol 1 5%Tween80 2 65%D5W Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	20.000mg/ml (34.32mM)	Taking the 1 mL working solution as an example, add 300 μL of clarified propylene glycol stock solution of 66.67 mg/ml to 50 μL of Tween 80, mix evenly to clarify it; then continue to add 650 μL of D5W to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	PI3Kδ (Cell-free assay) 0.1 nM PI3Kβ (Cell-free assay) 0.5 nM PI3Kα (Cell-free assay) 4 nM DNA-PK (Cell-free assay) 5 nM PI3Kγ (Cell-free assay) 0.59 μM
In vitro	KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM this compound inhibits cell proliferation by more than 95% in MCF7 cells but only by 55% in SW620 cells.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22576130/ [2] http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/A138

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your product page the in vivo solubility for S8045 in 30% Propylene glycol, 5% Tween 80, 65% D5W is up to 20 mg/mL, but in the reference listed "Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K." they use Phosphoric Acid pH 5 to resuspend it. I am curious if you have any information on solubility in phosphoric acid pH 5 for this compound.

Answer:
30% Propylene glycol, 5% Tween 80, 65% D5W to 20 mg/mL is the vehicle we tested in our lab for this compound, it's a suspension and can only be used as oral gavage. Phosphoric Acid pH 5 is from the reference, but we didn't test its solubility in it.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

KU-0060648 DNA-PK/PI3K inhibitor

Chemical Structure

Molecular Weight: 582.71